Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

[1]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[2]  D. Faller,et al.  Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. , 2018, Blood.

[3]  J. Reeves,et al.  Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes , 2017, Cancer.

[4]  C. Bloomfield,et al.  Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Gore,et al.  Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults , 2013, Haematologica.

[6]  H. Kantarjian,et al.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. , 2011, Seminars in oncology.

[7]  B. Esterni,et al.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Ping Li,et al.  Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. , 2010, Molecular cell.

[9]  Peter G. Smith,et al.  Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer , 2009, Clinical Cancer Research.

[10]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[11]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[12]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[13]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.